Acceleration of onset of action in schedule-induced polydipsia: Combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 1, 2004, Pages 69-75

  Hogg, Sandy ^a   Dalvi, Ashutosh ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Fast onset; Fluoxetine; GR 127935; Schedule induced polydipsia; SSRI; WAY 100635

Indexed keywords

DRINKING WATER; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; FLUID INTAKE; LATENT PERIOD; MALE; NEUROTRANSMISSION; NONHUMAN; POLYDIPSIA; PRIORITY JOURNAL; RANDOMIZATION; RAT; TRAINING; WATER AVAILABILITY;

EID: 0347285262     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.09.020     Document Type: Article

References (61)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
2. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19:1996;378-383.
3. Asnis G.M., Hameedi F.A., Goddard A.W., Potkin S.G., Black D., Jameel M., Desagani K., Woods S.W. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 103(1):2001;1-14.
4. Auerbach S.B., Hjorth S. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;597-606.
5. Bakish D., Hooper C.L., Thornton M.D., Wiens A., Miller C.A., Thibaudeau C.A. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int. Clin. Psychopharmacol. 12:1997;91-97.
6. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15:1993;243-245.
7. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
8. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
9. Blier P., Bouchard C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br. J. Pharmacol. 113:1994;485-495.
10. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
11. Blier P., Chaput Y., de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1998;246-254.
12. Bosker F.J., van Esseveldt K.E., Klompmakers A.A., Westenberg H.G. Chronic treatment with fluvoxamine by osmotic minipumps fails to induce persistent functional changes in central 5-HT1A and 5-HT1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology (Berl.). 117:1995;358-363.
13. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
14. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 333:1996;342-348.
15. Cremers T.I., Spoelstra E.N., de Boer P., Bosker F.J., Mork A., den Boer J.A., Westerink B.H., Wikstrom H.V. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397:2000;351-357.
16. Cryan J.F., McGrath C., Leonard B.E., Norman T.R. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur. J. Pharmacol. 352:1998;23-28.
17. Cryan J.F., Kelliher P., Kelly J.P., Leonard B.E. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J. Psychopharmacol. 13:1999;278-283.
18. Dantzer R., Mormede P. Pituitary-adrenal consequences of adjunctive activities in pigs. Horm. Behav. 15:1981;386-395.
19. Da-Rocha M.A., Puech A.J., Thiebot M.H. Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. J. Psychopharmacol. 11:1997;211-218.
20. Davidson C., Stamford J.A. The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT1A and 5-HT1B/D receptor antagonists. Neurosci. Lett. 188:1995;41-44.
21. Davidson C., Stamford J.A. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus. Brain Res. 760:1997;238-242.
22. de Almeida R.M., Nikulina E.M., Faccidomo S., Fish E.W., Miczek K.A. Zolmitriptan - a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology (Berl.). 157:2001;131-141. [JID- 7608025].
23. Dinan T.G., Scott L.V. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors? Journal Serotonin Res. 3:1997;119-121.
24. Falk J.L. Production of polydipsia in normal rats by an intermittent food schedule. Science. 133:1961;195-196.
25. Gardier A.M., Malagie I., Trillat A.C., Jacquot C., Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of antidepressant drugs: recent findings from microdialysis studies. Fundam. Clin. Pharmacol. 10:1995;16-27.
26. Gobert A., Rivet J.M., Cistarelli L., Millan M.J. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68:1997;1159-1163.
27. Hervas I., Queiroz C.M., Adell A. Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br. J. Pharmacol. 130:2000;160-166.
28. Hjorth S., Auerbach S.B. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology. 33:1994;331-334.
29. Hudson R., Singer G. Polydipsia in the monkey generated by visual display schedules. Physiol. Behav. 22:1979;379-381.
30. Jolas T., Haj-Dahmane S., Kidd E.J., Langlois X., Lanfumey L., Fattaccini C.M., Vantalon V., Laporte A.M., Adrien J., Gozlan H. Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J. Pharmacol. Exp. Ther. 268:1994;1432-1443.
31. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74:1997;299-316.
32. Knobelman D.A., Hen R., Lucki I. Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse. J. Pharmacol. Exp. Ther. 298:2001;1083-1091.
33. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274:1995;866-876.
34. Maes M., Vandoolaeghe E., Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J. Affect. Disord. 41:1996;201-210.
35. Martin J.R., Bos M., Jenck F., Moreau J., Mutel V., Sleight A.J., Wichmann J., Andrews J.S., Berendsen H.H., Broekkamp C.L., Ruigt G.S., Kohler C., Delft A.M. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 286:1998;913-924.
36. Martin J.R., Ballard T.M., Higgins G.A. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol. Biochem. Behav. 71:2002;615-625. [JID-0367050].
37. Mayorga A.J., Dalvi A., Page M.E., Zimov-Levinson S., Hen R., Lucki I. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298:2001;1101-1107.
38. Mitchell P.J., Redfern P.H. Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635. Behav. Pharmacol. 8:1997;585-606.
39. Moret C., Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295:1996;189-197.
40. O'Connor J.J., Kruk Z.L. Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro. Brain Res. 640:1994;328-335.
41. O'Neill M.F., Fernandez A.G., Palacios J.M. GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol. Biochem. Behav. 53:1996;535-539.
42. Palfai T., Kutscher C.L., Symons J.P. Schedule-induced polydipsia in the mouse. Physiol. Behav. 6:1971;461-462.
43. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
44. Porter J.H., Bryant W.E. Acquisition of schedule-induced polydipsia in the Mongolian gerbil. Physiol. Behav. 21:1978;825-827.
45. Porter J.H., Kenshalo D.R. Schedule-induced drinking following omission of reinforcement in the rhesus monkey. Physiol. Behav. 12:1974;1075-1077.
46. Przegalinski E., Moryl E., Papp M. The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology. 34:1995;1305-1310.
47. Redrobe J.P., Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl.). 138:1998;198-206.
48. Roberts C., Belenguer A., Middlemiss D.N., Routledge C. Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur. J. Pharmacol. 346:1998;175-180.
49. Rollema H., Clarke T., Sprouse J.S., Schulz D.W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem. 67:1996;2204-2207.
50. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171:1994;183-186.
51. Stanhope K.J., Dourish C.T. Effects of 5-HT1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat. Psychopharmacology (Berl.). 128:1996;293-303.
52. Svensson T.H. Attenuated feed-back inhibition of brain serotonin synthesis following chronic administration of imipramine. Naunyn-Schmiedeberg's Arch. Pharmacol. 302:1978;115-118.
53. Tazi A., Dantzer R., Mormede P., Le Moal M. Pituitary-adrenal correlates of schedule-induced polydipsia and wheel running in rats. Behav. Brain. Res. 19:1986;249-256.
54. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81-89.
55. Trillat A.C., Malagie I., Bourin M., Jacquot C., Hen R., Gardier A.M. Homozygote mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors. Comptes Rendus Seances Soc. Biol. Fil. 192:1998;1139-1147.
56. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., Goa K.L. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs. 16(6):2002;425-434.
57. Wallace M., Singer G. Schedule induced behavior: a review of its generality, determinants and pharmacological data. Pharmacol. Biochem. Behav. 5:1976;483-490.
58. Wallace M., Singer G., Wayner M.J., Cook P. Adjunctive behavior in humans during game playing. Physiol. Behav. 14:1975;651-654.
59. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.). 134:1997;319-329.
60. Wilson S., Spencer B. Schedule-induced polydipsia: species limitations. Psychol. Rep. 36:1975;863-866.
61. Woods A., Smith C., Szewczak M., Dunn R.W., Cornfeldt M., Corbett R. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl.). 112:1993;195-198.